

ASX RELEASE

24 June 2019

Dr John Lambert appointed as new CEO

Amplia Therapeutics (ASX: ATX) is pleased to announce the appointment of Dr John Lambert as Chief Executive Officer. Long serving former CEO, Mr Simon Wilkinson, will remain on the Company's Board as a non-executive director.

Based in Melbourne, Dr Lambert has worked in drug discovery and development for over 20 years. His previous roles have included senior management positions at Biota Holdings Limited and Medicines Development for Global Health. His experience spans the full drug development lifecycle from early discovery, intellectual property protection, licensing, product development, and regulatory approval. John has been Amplia's Operations Manager since August 2018 and has been directing all aspects of the Company's clinical enabling work since that time.

"The appointment of Dr Lambert as Chief Executive is another important step in the transformation of Amplia" said Chairman Dr Warwick Tong. "John's experience and enthusiasm make him the ideal candidate to deliver the near and medium term clinical development milestones we have set for the Company".

The Board of Amplia acknowledges the hard work and dedication of outgoing CEO Simon Wilkinson. "Mr Wilkinson has been a great champion for our Company for many years and we are especially pleased that he will be continuing as a director to ensure a smooth transition for Dr Lambert" said Dr Tong.

Dr Lambert commented "I am delighted to take up the Chief Executive role at Amplia Therapeutics. I'm particularly excited to be working alongside a Board with so much industry experience and I am looking forward to working with them to deliver on our objectives and drive value for our shareholders."

Details of Dr Lambert's remuneration as CEO follow.

- End -

For Further Information

Dr Warwick Tong, Chairman

+61 450 296 930

www.ampliatx.com

Material terms of Dr Lambert's employment agreement are as follows:

Total Fixed Remuneration:	\$197,000 per annum which includes – a) Base salary of \$180,000 per annum, b) Compulsory superannuation.
Sign-on Incentive:	To be granted after 3 months – 1.2 million options with exercise price at \$0.165 4 years vesting (accelerated upon completion of Phase 1 trial) Expire 24 June 2024.
Long Term Incentives:	Eligible to participate at the discretion of the Company.
Short Term Incentives:	Bonus incentive of up to 25% of Total Fixed Remuneration payable in cash or equity based on performance against performance milestones to be agreed and at the Board's discretion.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis.

About Amplia's Pipeline

Amplia's initial clinical development pipeline currently comprises two novel orally available small molecule FAK inhibitors:

- AMP945 – Highly selective (FAK-only)
- AMP886 – Highly differentiated, multi-action (FAK/FLT3/VEGFR3)

Preclinically, both AMP945 and AMP886 have demonstrated excellent potency and selectivity, together with very promising pharmacokinetics and physical-chemistry properties. Amplia is positioning AMP945 for the initiation of Phase I clinical trials in 2020.

Contact:

John Lambert, CEO
john@ampliatx.com
+61 (0)409 525 259